Theravance Biopharma, Inc. (TBPH)
16.51
-0.16
(-0.96%)
USD |
NASDAQ |
May 14, 16:00
16.10
-0.41
(-2.48%)
After-Hours: 20:00
Theravance Biopharma Cash from Investing (Quarterly) : 52.59M for March 31, 2026
Cash from Investing (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Data
Cash From Investing Definition
Cash from Investing is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall investing activities of the company. A few examples of investing activities include net change in PP&E, and net divestitures.
Cash from Investing (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Cash from Investing (Quarterly) Benchmarks
| Viatris, Inc. | 277.40M |
| Relmada Therapeutics, Inc. | -135.23M |
| Indivior Pharmaceuticals, Inc. | -19.00M |
| Corcept Therapeutics, Inc. | 4.542M |
| Assertio Holdings, Inc. | 15.11M |
Cash from Investing (Quarterly) Related Metrics
| Cash from Operations (Quarterly) | 73.28M |
| Cash from Financing (Quarterly) | -5.577M |
| Free Cash Flow | 268.74M |
| Free Cash Flow Per Share (Quarterly) | 1.429 |
| Free Cash Flow to Equity (Quarterly) | 75.48M |
| Free Cash Flow to Firm (Quarterly) | 73.28M |
| Free Cash Flow Yield | 31.46% |